December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abivax SA - American Depositary Shares (NQ:ABVX)

142.52 +0.21 (+0.15%)
Streaming Delayed Price Updated: 1:12 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Abivax SA - American Depositary Shares

< Previous 1 2 Next >
News headline image
Abivax to be Added to Nasdaq Biotechnology Index
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
From Abivax
Via GlobeNewswire
News headline image
Abivax Presents Third Quarter 2025 Financial Results
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
From Abivax
Via GlobeNewswire
News headline image
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
From Abivax
Via GlobeNewswire
News headline image
Abivax Presents First Half 2025 Financial Results
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Closing of $747.5 Million Public Offering
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
From Abivax
Via GlobeNewswire
News headline image
Abivax announces trading resumption of its ordinary shares on Euronext Paris
From Abivax
Via GlobeNewswire
News headline image
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Launch of Public Offering
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Results of its June 6, 2025 Annual General Meeting
From Abivax
Via GlobeNewswire
News headline image
Abivax Presents First Quarter 2025 Financial Results
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
From Abivax
Via GlobeNewswire
News headline image
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Full Year 2024 Financial Results
From Abivax
Via GlobeNewswire
News headline image
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
From Abivax
Via GlobeNewswire
News headline image
Abivax Publishes 2025 Financial Calendar
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
From Abivax
Via GlobeNewswire
News headline image
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces a Change to the Composition of its Board of Directors
From Abivax
Via GlobeNewswire
News headline image
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
From Abivax
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.